nach oben

Clinical & Experimental Metastasis

Erschienen in:

06.01.2018 | Research Paper

Chemotherapy-induced metastasis: mechanisms and translational opportunities

verfasst von: George S. Karagiannis, John S. Condeelis, Maja H. Oktay

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Tumors often overcome the cytotoxic effects of chemotherapy through either acquired or environment-mediated drug resistance. In addition, signals from the microenvironment obfuscate the beneficial effects of chemotherapy and may facilitate progression and metastatic dissemination. Seminal mediators in chemotherapy-induced metastasis appear to be a wide range of hematopoietic, mesenchymal and immune progenitor cells, originating from the bone marrow. The actual purpose of these cells is to orchestrate the repair response to the cytotoxic damage of chemotherapy. However, these repair responses are exploited by tumor cells at every step of the metastatic cascade, ranging from tumor cell invasion, intravasation and hematogenous dissemination to extravasation and effective colonization at the metastatic site. A better understanding of the mechanistic underpinnings of chemotherapy-induced metastasis will allow us to better predict which patients are more likely to exhibit pro-metastatic responses to chemotherapy and will help develop new therapeutic strategies to neutralize chemotherapy-driven prometastatic changes.

Husemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, Forni G, Eils R, Fehm T, Riethmuller G, Klein CA (2008) Systemic spread is an early step in breast cancer. Cancer Cell 13(1):58–68. https://doi.org/10.1016/j.ccr.2007.12.003 PubMedCrossRef

Sanger N, Effenberger KE, Riethdorf S, Van Haasteren V, Gauwerky J, Wiegratz I, Strebhardt K, Kaufmann M, Pantel K (2011) Disseminated tumor cells in the bone marrow of patients with ductal carcinoma in situ. Int J Cancer 129(10):2522–2526. https://doi.org/10.1002/ijc.25895 PubMedCrossRef

Martin OA, Anderson RL, Narayan K, MacManus MP (2017) Does the mobilization of circulating tumour cells during cancer therapy cause metastasis? Nat Rev Clin Oncol 14(1):32–44. https://doi.org/10.1038/nrclinonc.2016.128 PubMedCrossRef

Ibragimova MK, Tsyganov MM, Litviakov NV (2017) Natural and chemotherapy-induced clonal evolution of tumors. Biochemistry Biokhimiia 82(4):413–25. https://doi.org/10.1134/S0006297917040022 PubMedCrossRef

Daenen LG, Houthuijzen JM, Cirkel GA, Roodhart JM, Shaked Y, Voest EE (2014) Treatment-induced host-mediated mechanisms reducing the efficacy of antitumor therapies. Oncogene 33(11):1341–1347. https://doi.org/10.1038/onc.2013.94 PubMedCrossRef

Daenen LG, Roodhart JM, van Amersfoort M, Dehnad M, Roessingh W, Ulfman LH, Derksen PW, Voest EE (2011) Chemotherapy enhances metastasis formation via VEGFR-1-expressing endothelial cells. Cancer Res 71(22):6976–6985. https://doi.org/10.1158/0008-5472.CAN-11-0627 PubMedCrossRef

Wu YJ, Muldoon LL, Dickey DT, Lewin SJ, Varallyay CG, Neuwelt EA (2009) Cyclophosphamide enhances human tumor growth in nude rat xenografted tumor models. Neoplasia 11(2):187–195PubMedPubMedCentralCrossRef

Valastyan S, Weinberg RA (2011) Tumor metastasis: molecular insights and evolving paradigms. Cell 147(2):275–292. https://doi.org/10.1016/j.cell.2011.09.024 PubMedPubMedCentralCrossRef

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674. https://doi.org/10.1016/j.cell.2011.02.013 PubMedCrossRef

10.

Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. J Clin Investig 119(6):1420–1428. https://doi.org/10.1172/JCI39104 PubMedCrossRef

11.

Kalluri R (2009) EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Investig 119(6):1417–1419. https://doi.org/10.1172/JCI39675 PubMedCrossRef

12.

Ye X, Weinberg RA (2015) Epithelial-mesenchymal plasticity: a central regulator of cancer progression. Trends Cell Biol 25(11):675–686. https://doi.org/10.1016/j.tcb.2015.07.012 PubMedPubMedCentralCrossRef

13.

Chaffer CL, San Juan BP, Lim E, Weinberg RA (2016) EMT, cell plasticity and metastasis. Cancer Metastasis Rev 35(4):645–654. https://doi.org/10.1007/s10555-016-9648-7 PubMedCrossRef

14.

Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139(5):871–890. https://doi.org/10.1016/j.cell.2009.11.007 PubMedCrossRef

15.

Yilmaz M, Christofori G (2009) EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 28(1–2):15–33. https://doi.org/10.1007/s10555-008-9169-0 PubMedCrossRef

16.

Cavallaro U, Schaffhauser B, Christofori G (2002) Cadherins and the tumour progression: is it all in a switch? Cancer Lett 176(2):123–128PubMedCrossRef

17.

Cavallaro U, Christofori G (2004) Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer 4(2):118–132. https://doi.org/10.1038/nrc1276 PubMedCrossRef

18.

De Wever O, Pauwels P, De Craene B, Sabbah M, Emami S, Redeuilh G, Gespach C, Bracke M, Berx G (2008) Molecular and pathological signatures of epithelial-mesenchymal transitions at the cancer invasion front. Histochem Cell Biol 130(3):481–494. https://doi.org/10.1007/s00418-008-0464-1 PubMedPubMedCentralCrossRef

19.

Wicki A, Lehembre F, Wick N, Hantusch B, Kerjaschki D, Christofori G (2006) Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell 9(4):261–272. https://doi.org/10.1016/j.ccr.2006.03.010 PubMedCrossRef

20.

Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong ST, Choi H, El Rayes T, Ryu S, Troeger J, Schwabe RF, Vahdat LT, Altorki NK, Mittal V, Gao D (2015) Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527(7579):472–476. https://doi.org/10.1038/nature15748 PubMedPubMedCentralCrossRef

21.

Shapiro IM, Cheng AW, Flytzanis NC, Balsamo M, Condeelis JS, Oktay MH, Burge CB, Gertler FB (2011) An EMT-driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype. PLoS Genet 7(8):e1002218. https://doi.org/10.1371/journal.pgen.1002218 PubMedPubMedCentralCrossRef

22.

Roussos ET, Goswami S, Balsamo M, Wang Y, Stobezki R, Adler E, Robinson BD, Jones JG, Gertler FB, Condeelis JS, Oktay MH (2011) Mena invasive (Mena(INV)) and Mena11a isoforms play distinct roles in breast cancer cell cohesion and association with TMEM. Clin Exp Metastasis 28(6):515–527. https://doi.org/10.1007/s10585-011-9388-6 PubMedPubMedCentralCrossRef

23.

Di Modugno F, Iapicca P, Boudreau A, Mottolese M, Terrenato I, Perracchio L, Carstens RP, Santoni A, Bissell MJ, Nistico P (2012) Splicing program of human MENA produces a previously undescribed isoform associated with invasive, mesenchymal-like breast tumors. Proc Natl Acad Sci USA 109(47):19280–19285. https://doi.org/10.1073/pnas.1214394109 PubMedCrossRef

24.

Oudin MJ, Hughes SK, Rohani N, Moufarrej MN, Jones JG, Condeelis JS, Lauffenburger DA, Gertler FB (2016) Characterization of the expression of the pro-metastatic Mena(INV) isoform during breast tumor progression. Clin Exp Metastasis 33(3):249–261. https://doi.org/10.1007/s10585-015-9775-5 PubMedCrossRef

25.

Balsamo M, Mondal C, Carmona G, McClain LM, Riquelme DN, Tadros J, Ma D, Vasile E, Condeelis JS, Lauffenburger DA, Gertler FB (2016) The alternatively-included 11a sequence modifies the effects of Mena on actin cytoskeletal organization and cell behavior. Sci Rep 6:35298. https://doi.org/10.1038/srep35298 PubMedPubMedCentralCrossRef

26.

Karagiannis GS, Pastoriza JM, Wang Y, Harney AS, Entenberg D, Pignatelli J, Sharma VP, Xue EA, Cheng E, D’Alfonso TM, Jones JG, Anampa J, Rohan TE, Sparano JA, Condeelis JS, Oktay MH (2017) Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism. Sci Transl Med. https://doi.org/10.1126/scitranslmed.aan0026 PubMedPubMedCentralCrossRef

27.

Forse CL, Agarwal S, Pinnaduwage D, Gertler F, Condeelis JS, Lin J, Xue X, Johung K, Mulligan AM, Rohan TE, Bull SB, Andrulis IL (2015) Menacalc, a quantitative method of metastasis assessment, as a prognostic marker for axillary node-negative breast cancer. BMC Cancer 15:483. https://doi.org/10.1186/s12885-015-1468-6 PubMedPubMedCentralCrossRef

28.

Agarwal S, Gertler FB, Balsamo M, Condeelis JS, Camp RL, Xue X, Lin J, Rohan TE, Rimm DL (2012) Quantitative assessment of invasive mena isoforms (Menacalc) as an independent prognostic marker in breast cancer. Breast Cancer Res 14(5):R124. https://doi.org/10.1186/bcr3318 PubMedPubMedCentralCrossRef

29.

Philippar U, Roussos ET, Oser M, Yamaguchi H, Kim HD, Giampieri S, Wang Y, Goswami S, Wyckoff JB, Lauffenburger DA, Sahai E, Condeelis JS, Gertler FB (2008) A Mena invasion isoform potentiates EGF-induced carcinoma cell invasion and metastasis. Dev Cell 15(6):813–828. https://doi.org/10.1016/j.devcel.2008.09.003 PubMedPubMedCentralCrossRef

30.

Hughes SK, Oudin MJ, Tadros J, Neil J, Del Rosario A, Joughin BA, Ritsma L, Wyckoff J, Vasile E, Eddy R, Philippar U, Lussiez A, Condeelis JS, van Rheenen J, White F, Lauffenburger DA, Gertler FB (2015) PTP1B-dependent regulation of receptor tyrosine kinase signaling by the actin-binding protein Mena. Mol Biol Cell 26(21):3867–3878. https://doi.org/10.1091/mbc.E15-06-0442 PubMedPubMedCentralCrossRef

31.

Leung E, Xue A, Wang Y, Rougerie P, Sharma VP, Eddy R, Cox D, Condeelis J (2017) Blood vessel endothelium-directed tumor cell streaming in breast tumors requires the HGF/C-Met signaling pathway. Oncogene 36(19):2680–2692. https://doi.org/10.1038/onc.2016.421 PubMedCrossRef

32.

Entenberg D, Wyckoff J, Gligorijevic B, Roussos ET, Verkhusha VV, Pollard JW, Condeelis J (2011) Setup and use of a two-laser multiphoton microscope for multichannel intravital fluorescence imaging. Nat Protoc 6(10):1500–1520. https://doi.org/10.1038/nprot.2011.376 PubMedPubMedCentralCrossRef

33.

Oudin MJ, Jonas O, Kosciuk T, Broye LC, Guido BC, Wyckoff J, Riquelme D, Lamar JM, Asokan SB, Whittaker C, Ma D, Langer R, Cima MJ, Wisinski KB, Hynes RO, Lauffenburger DA, Keely PJ, Bear JE, Gertler FB (2016) Tumor cell-driven extracellular matrix remodeling drives haptotaxis during metastatic progression. Cancer Discov 6(5):516–531. https://doi.org/10.1158/2159-8290.CD-15-1183 PubMedPubMedCentralCrossRef

34.

Weidmann MD, Surve CR, Eddy RJ, Chen X, Gertler FB, Sharma VP, Condeelis JS (2016) MenaINV dysregulates cortactin phosphorylation to promote invadopodium maturation. Sci Rep 6:36142. https://doi.org/10.1038/srep36142 PubMedPubMedCentralCrossRef

35.

Gligorijevic B, Wyckoff J, Yamaguchi H, Wang Y, Roussos ET, Condeelis J (2012) N-WASP-mediated invadopodium formation is involved in intravasation and lung metastasis of mammary tumors. J Cell Sci 125(Pt 3):724–734. https://doi.org/10.1242/jcs.092726 PubMedPubMedCentralCrossRef

36.

Eddy RJ, Weidmann MD, Sharma VP, Condeelis JS (2017) Tumor cell invadopodia: invasive protrusions that orchestrate metastasis. Trends Cell Biol 27(8):595–607. https://doi.org/10.1016/j.tcb.2017.03.003 PubMedCrossRefPubMedCentral

37.

Patsialou A, Bravo-Cordero JJ, Wang Y, Entenberg D, Liu H, Clarke M, Condeelis JS (2013) Intravital multiphoton imaging reveals multicellular streaming as a crucial component of in vivo cell migration in human breast tumors. Intravital 2(2):e25294. https://doi.org/10.4161/intv.25294 PubMedPubMedCentralCrossRef

38.

Roussos ET, Balsamo M, Alford SK, Wyckoff JB, Gligorijevic B, Wang Y, Pozzuto M, Stobezki R, Goswami S, Segall JE, Lauffenburger DA, Bresnick AR, Gertler FB, Condeelis JS (2011) Mena invasive (MenaINV) promotes multicellular streaming motility and transendothelial migration in a mouse model of breast cancer. J Cell Sci 124(Pt 13):2120–2131. https://doi.org/10.1242/jcs.086231 PubMedPubMedCentralCrossRef

39.

Sharma VP, Beaty BT, Patsialou A, Liu H, Clarke M, Cox D, Condeelis JS, Eddy RJ (2012) Reconstitution of in vivo macrophage-tumor cell pairing and streaming motility on one-dimensional micro-patterned substrates. Intravital 1(1):77–85. https://doi.org/10.4161/intv.22054 PubMedPubMedCentralCrossRef

40.

Harney AS, Wang Y, Condeelis JS, Entenberg D (2016) Extended time-lapse intravital imaging of real-time multicellular dynamics in the tumor microenvironment. J Vis Exp. https://doi.org/10.3791/54042 PubMedPubMedCentralCrossRef

41.

Bravo-Cordero JJ, Hodgson L, Condeelis J (2012) Directed cell invasion and migration during metastasis. Curr Opin Cell Biol 24(2):277–283. https://doi.org/10.1016/j.ceb.2011.12.004 PubMedCrossRef

42.

Roussos ET, Condeelis JS, Patsialou A (2011) Chemotaxis in cancer. Nat Rev Cancer 11(8):573–587. https://doi.org/10.1038/nrc3078 PubMedPubMedCentralCrossRef

43.

Patsialou A, Wyckoff J, Wang Y, Goswami S, Stanley ER, Condeelis JS (2009) Invasion of human breast cancer cells in vivo requires both paracrine and autocrine loops involving the colony-stimulating factor-1 receptor. Cancer Res 69(24):9498–9506. https://doi.org/10.1158/0008-5472.CAN-09-1868 PubMedPubMedCentralCrossRef

44.

Pignatelli J, Bravo-Cordero JJ, Roh-Johnson M, Gandhi SJ, Wang Y, Chen X, Eddy RJ, Xue A, Singer RH, Hodgson L, Oktay MH, Condeelis JS (2016) Macrophage-dependent tumor cell transendothelial migration is mediated by Notch1/MenaINV-initiated invadopodium formation. Sci Rep 6:37874. https://doi.org/10.1038/srep37874 PubMedPubMedCentralCrossRef

45.

Karagiannis GS, Goswami S, Jones JG, Oktay MH, Condeelis JS (2016) Signatures of breast cancer metastasis at a glance. J Cell Sci 129(9):1751–1758. https://doi.org/10.1242/jcs.183129 PubMedPubMedCentralCrossRef

46.

Robinson BD, Sica GL, Liu YF, Rohan TE, Gertler FB, Condeelis JS, Jones JG (2009) Tumor microenvironment of metastasis in human breast carcinoma: a potential prognostic marker linked to hematogenous dissemination. Clin Cancer Res 15(7):2433–2441. https://doi.org/10.1158/1078-0432.CCR-08-2179 PubMedPubMedCentralCrossRef

47.

Rohan TE, Xue X, Lin HM, D’Alfonso TM, Ginter PS, Oktay MH, Robinson BD, Ginsberg M, Gertler FB, Glass AG, Sparano JA, Condeelis JS, Jones JG (2014) Tumor microenvironment of metastasis and risk of distant metastasis of breast cancer. J Natl Cancer Inst https://doi.org/10.1093/jnci/dju136 PubMedPubMedCentralCrossRef

48.

Sparano JA, Gray R, Oktay MH, Entenberg D, Rohan T, Xue X, Donovan M, Peterson M, Hamilton AS, D’Alfonso DA, Goldstein T, Gertler LJ, Davidson F, Condeelis NE, Jones J J. A novel metastasis biomarker (MetaSite Breast™ Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early stage breast cancer npj breast cancer. NPJ Breast Cancer 3:42

49.

Harney AS, Arwert EN, Entenberg D, Wang Y, Guo P, Qian BZ, Oktay MH, Pollard JW, Jones JG, Condeelis JS (2015) Real-time imaging reveals local, transient vascular permeability, and tumor cell intravasation stimulated by TIE2hi macrophage-derived VEGFA. Cancer Discov 5(9):932–943. https://doi.org/10.1158/2159-8290.CD-15-0012 PubMedPubMedCentralCrossRef

50.

Patsialou A, Wang Y, Lin J, Whitney K, Goswami S, Kenny PA, Condeelis JS (2012) Selective gene-expression profiling of migratory tumor cells in vivo predicts clinical outcome in breast cancer patients. Breast Cancer Res 14(5):R139. https://doi.org/10.1186/bcr3344 PubMedPubMedCentralCrossRef

51.

Pignatelli J, Goswami S, Jones JG, Rohan TE, Pieri E, Chen X, Adler E, Cox D, Maleki S, Bresnick A, Gertler FB, Condeelis JS, Oktay MH (2014) Invasive breast carcinoma cells from patients exhibit MenaINV- and macrophage-dependent transendothelial migration. Science Signal 7(353):ra112. https://doi.org/10.1126/scisignal.2005329 CrossRef

52.

Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219(4587):983–985PubMedCrossRef

53.

Bates DO, Lodwick D, Williams B (1999) Vascular endothelial growth factor and microvascular permeability. Microcirculation 6(2):83–96PubMedCrossRef

54.

Lee YC (2005) The involvement of VEGF in endothelial permeability: a target for anti-inflammatory therapy. Curr Opin Investig Drugs 6(11):1124–1130PubMed

55.

Stan RV, Roberts WG, Predescu D, Ihida K, Saucan L, Ghitescu L, Palade GE (1997) Immunoisolation and partial characterization of endothelial plasmalemmal vesicles (caveolae). Mol Biol Cell 8(4):595–605PubMedPubMedCentralCrossRef

56.

Roberts WG, Palade GE (1995) Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 108(Pt 6):2369–2379PubMed

57.

Roberts WG, Palade GE (1997) Neovasculature induced by vascular endothelial growth factor is fenestrated. Cancer Res 57(4):765–772PubMed

58.

Roberts WG, Delaat J, Nagane M, Huang S, Cavenee WK, Palade GE (1998) Host microvasculature influence on tumor vascular morphology and endothelial gene expression. Am J Pathol 153(4):1239–1248. https://doi.org/10.1016/S0002-9440(10)65668-4 PubMedPubMedCentralCrossRef

59.

Kadioglu E, De Palma M (2015) Cancer metastasis: perivascular macrophages under watch. Cancer Discov 5(9):906–908. https://doi.org/10.1158/2159-8290.CD-15-0819 PubMedCrossRef

60.

De Palma M, Murdoch C, Venneri MA, Naldini L, Lewis CE (2007) Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications. Trends Immunol 28(12):519–524. https://doi.org/10.1016/j.it.2007.09.004 PubMedCrossRef

61.

Lewis CE, Harney AS, Pollard JW (2016) The multifaceted role of perivascular macrophages in tumors. Cancer Cell 30(1):18–25. https://doi.org/10.1016/j.ccell.2016.05.017 PubMedPubMedCentralCrossRef

62.

Harney AS, Karagiannis GS, Pignatelli J, Smith BD, Kadioglu E, Wise SC, Hood MM, Kaufman MD, Leary CB, Lu WP, Al-Ani G, Chen X, Entenberg D, Oktay MH, Wang Y, Chun L, De Palma M, Jones JG, Flynn DL, Condeelis JS (2017) The selective Tie2 inhibitor rebastinib blocks recruitment and function of Tie2(Hi) macrophages in breast cancer and pancreatic neuroendocrine tumors. Mol Cancer Ther 16(11):2486–2501. https://doi.org/10.1158/1535-7163.MCT-17-0241 PubMedCrossRef

63.

Kawakami Y, Ii M, Matsumoto T, Kuroda R, Kuroda T, Kwon SM, Kawamoto A, Akimaru H, Mifune Y, Shoji T, Fukui T, Kurosaka M, Asahara T (2015) SDF-1/CXCR4 axis in Tie2-lineage cells including endothelial progenitor cells contributes to bone fracture healing. J Bone Miner Res 30(1):95–105. https://doi.org/10.1002/jbmr.2318 PubMedCrossRef

64.

Kalbasi A, Komar C, Tooker GM, Liu M, Lee JW, Gladney WL, Ben-Josef E, Beatty GL (2017) Tumor-derived CCL2 mediates resistance to radiotherapy in pancreatic ductal adenocarcinoma. Clin Cancer Res 23(1):137–148. https://doi.org/10.1158/1078-0432.CCR-16-0870 PubMedCrossRef

65.

Jin DK, Shido K, Kopp HG, Petit I, Shmelkov SV, Young LM, Hooper AT, Amano H, Avecilla ST, Heissig B, Hattori K, Zhang F, Hicklin DJ, Wu Y, Zhu Z, Dunn A, Salari H, Werb Z, Hackett NR, Crystal RG, Lyden D, Rafii S (2006) Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat Med 12(5):557–567. https://doi.org/10.1038/nm1400 PubMedPubMedCentralCrossRef

66.

Welford AF, Biziato D, Coffelt SB, Nucera S, Fisher M, Pucci F, Di Serio C, Naldini L, De Palma M, Tozer GM, Lewis CE (2011) TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice. J Clin Investig 121(5):1969–1973. https://doi.org/10.1172/JCI44562 PubMedCrossRef

67.

Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, Wang-Gillam A, Goedegebuure SP, Linehan DC, DeNardo DG (2014) CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res 74(18):5057–5069. https://doi.org/10.1158/0008-5472.CAN-13-3723 PubMedPubMedCentralCrossRef

68.

Lewis CE, De Palma M, Naldini L (2007) Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2. Cancer Res 67(18):8429–8432. https://doi.org/10.1158/0008-5472.CAN-07-1684 PubMedCrossRef

69.

Saharinen P, Alitalo K (2011) The yin, the yang, and the angiopoietin-1. J Clin Investig 121(6):2157–2159. https://doi.org/10.1172/JCI58196 PubMedCrossRef

70.

Murakami M (2012) Signaling required for blood vessel maintenance: molecular basis and pathological manifestations. Int J Vasc Med 2012:293641. https://doi.org/10.1155/2012/293641 PubMedCrossRef

71.

Moore KA, Lemischka IR (2004) “Tie-ing” down the hematopoietic niche. Cell 118(2):139–140. https://doi.org/10.1016/j.cell.2004.07.006 PubMedCrossRef

72.

Arai F, Hirao A, Ohmura M, Sato H, Matsuoka S, Takubo K, Ito K, Koh GY, Suda T (2004) Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 118(2):149–161. https://doi.org/10.1016/j.cell.2004.07.004 PubMedCrossRef

73.

Ferrara N (2010) Role of myeloid cells in vascular endothelial growth factor-independent tumor angiogenesis. Curr Opin Hematol 17(3):219–224. https://doi.org/10.1097/MOH.0b013e3283386660 PubMedCrossRef

74.

Armulik A, Abramsson A, Betsholtz C (2005) Endothelial/pericyte interactions. Circ Res 97(6):512–523. https://doi.org/10.1161/01.RES.0000182903.16652.d7 PubMedCrossRef

75.

Song S, Ewald AJ, Stallcup W, Werb Z, Bergers G (2005) PDGFRbeta + perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol 7(9):870–879. https://doi.org/10.1038/ncb1288 PubMedPubMedCentralCrossRef

76.

Dasgupta A, Lim AR, Ghajar CM (2017) Circulating and disseminated tumor cells: harbingers or initiators of metastasis? Mol Oncol 11(1):40–61. https://doi.org/10.1002/1878-0261.12022 PubMedPubMedCentralCrossRef

77.

Koop S, MacDonald IC, Luzzi K, Schmidt EE, Morris VL, Grattan M, Khokha R, Chambers AF, Groom AC (1995) Fate of melanoma cells entering the microcirculation: over 80% survive and extravasate. Cancer Res 55(12):2520–2523PubMed

78.

Fidler IJ (1970) Metastasis: quantitative analysis of distribution and fate of tumor emboli labeled with 125 I-5-iodo-2′-deoxyuridine. J Natl Cancer Inst 45(4):773–782PubMed

79.

Ye X, Tam WL, Shibue T, Kaygusuz Y, Reinhardt F, Ng Eaton E, Weinberg RA (2015) Distinct EMT programs control normal mammary stem cells and tumour-initiating cells. Nature 525(7568):256–260. https://doi.org/10.1038/nature14897 PubMedPubMedCentralCrossRef

80.

Shibue T, Weinberg RA (2017) EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol 14(10):611–629. https://doi.org/10.1038/nrclinonc.2017.44 PubMedPubMedCentralCrossRef

81.

Lu H, Clauser KR, Tam WL, Frose J, Ye X, Eaton EN, Reinhardt F, Donnenberg VS, Bhargava R, Carr SA, Weinberg RA (2014) A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages. Nat Cell Biol 16(11):1105–1117. https://doi.org/10.1038/ncb3041 PubMedPubMedCentralCrossRef

82.

Sainz B Jr, Carron E, Vallespinos M, Machado HL (2016) Cancer stem cells and macrophages: implications in tumor biology and therapeutic strategies. Mediat Inflamm 2016:9012369. https://doi.org/10.1155/2016/9012369 CrossRef

83.

Sica A, Porta C, Amadori A, Pasto A (2017) Tumor-associated myeloid cells as guiding forces of cancer cell stemness. Cancer Immunol Immunother 66(8):1025–1036. https://doi.org/10.1007/s00262-017-1997-8 PubMedCrossRef

84.

Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M, Molina H, Kohsaka S, Di Giannatale A, Ceder S, Singh S, Williams C, Soplop N, Uryu K, Pharmer L, King T, Bojmar L, Davies AE, Ararso Y, Zhang T, Zhang H, Hernandez J, Weiss JM, Dumont-Cole VD, Kramer K, Wexler LH, Narendran A, Schwartz GK, Healey JH, Sandstrom P, Labori KJ, Kure EH, Grandgenett PM, Hollingsworth MA, de Sousa M, Kaur S, Jain M, Mallya K, Batra SK, Jarnagin WR, Brady MS, Fodstad O, Muller V, Pantel K, Minn AJ, Bissell MJ, Garcia BA, Kang Y, Rajasekhar VK, Ghajar CM, Matei I, Peinado H, Bromberg J, Lyden D (2015) Tumour exosome integrins determine organotropic metastasis. Nature 527(7578):329–335. https://doi.org/10.1038/nature15756 PubMedPubMedCentralCrossRef

85.

Steinbichler TB, Dudas J, Riechelmann H, Skvortsova II (2017) The role of exosomes in cancer metastasis. Semin Cancer Biol 44:170–181. https://doi.org/10.1016/j.semcancer.2017.02.006 PubMedCrossRef

86.

Costa-Silva B, Aiello NM, Ocean AJ, Singh S, Zhang H, Thakur BK, Becker A, Hoshino A, Mark MT, Molina H, Xiang J, Zhang T, Theilen TM, Garcia-Santos G, Williams C, Ararso Y, Huang Y, Rodrigues G, Shen TL, Labori KJ, Lothe IM, Kure EH, Hernandez J, Doussot A, Ebbesen SH, Grandgenett PM, Hollingsworth MA, Jain M, Mallya K, Batra SK, Jarnagin WR, Schwartz RE, Matei I, Peinado H, Stanger BZ, Bromberg J, Lyden D (2015) Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat Cell Biol 17(6):816–826. https://doi.org/10.1038/ncb3169 PubMedPubMedCentralCrossRef

87.

Becker A, Thakur BK, Weiss JM, Kim HS, Peinado H, Lyden D (2016) Extracellular vesicles in cancer: cell-to-cell mediators of metastasis. Cancer Cell 30(6):836–848. https://doi.org/10.1016/j.ccell.2016.10.009 PubMedPubMedCentralCrossRef

88.

Kaplan RN, Rafii S, Lyden D (2006) Preparing the “soil”: the premetastatic niche. Cancer Res 66(23):11089–11093. https://doi.org/10.1158/0008-5472.CAN-06-2407 PubMedPubMedCentralCrossRef

89.

Safarzadeh E, Orangi M, Mohammadi H, Babaie F, Baradaran B (2017) Myeloid-derived suppressor cells: important contributors to tumor progression and metastasis. J Cell Physiol. https://doi.org/10.1002/jcp.26075 PubMedCrossRef

90.

Wculek SK, Malanchi I (2015) Neutrophils support lung colonization of metastasis-initiating breast cancer cells. Nature 528(7582):413–417. https://doi.org/10.1038/nature16140 PubMedPubMedCentralCrossRef

91.

Malanchi I, Santamaria-Martinez A, Susanto E, Peng H, Lehr HA, Delaloye JF, Huelsken J (2011) Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 481(7379):85–89. https://doi.org/10.1038/nature10694 PubMedCrossRef

92.

Bragado P, Sosa MS, Keely P, Condeelis J, Aguirre-Ghiso JA (2012) Microenvironments dictating tumor cell dormancy. Recent Results Cancer Res 195:25–39. https://doi.org/10.1007/978-3-642-28160-0_3 PubMedPubMedCentralCrossRef

93.

Sosa MS, Bragado P, Aguirre-Ghiso JA (2014) Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat Rev Cancer 14(9):611–622. https://doi.org/10.1038/nrc3793 PubMedPubMedCentralCrossRef

94.

Fluegen G, Avivar-Valderas A, Wang Y, Padgen MR, Williams JK, Nobre AR, Calvo V, Cheung JF, Bravo-Cordero JJ, Entenberg D, Castracane J, Verkhusha V, Keely PJ, Condeelis J, Aguirre-Ghiso JA (2017) Phenotypic heterogeneity of disseminated tumour cells is preset by primary tumour hypoxic microenvironments. Nat Cell Biol 19(2):120–132. https://doi.org/10.1038/ncb3465 PubMedPubMedCentralCrossRef

95.

Byrd-Leifer CA, Block EF, Takeda K, Akira S, Ding A (2001) The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol. Eur J Immunol 31(8):2448–57PubMedCrossRef

96.

Iwasaki A, Medzhitov R (2004) Toll-like receptor control of the adaptive immune responses. Nat Immunol 5(10):987–995. https://doi.org/10.1038/ni1112 PubMedCrossRef

97.

Mittal D, Saccheri F, Venereau E, Pusterla T, Bianchi ME, Rescigno M (2010) TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells. EMBO J 29(13):2242–2252. https://doi.org/10.1038/emboj.2010.94 PubMedPubMedCentralCrossRef

98.

Volk-Draper L, Hall K, Griggs C, Rajput S, Kohio P, DeNardo D, Ran S (2014) Paclitaxel therapy promotes breast cancer metastasis in a TLR4-dependent manner. Cancer Res 74(19):5421–5434. https://doi.org/10.1158/0008-5472.CAN-14-0067 PubMedPubMedCentralCrossRef

99.

Ran S (2015) The role of TLR4 in chemotherapy-driven metastasis. Cancer Res 75(12):2405–2410. https://doi.org/10.1158/0008-5472.CAN-14-3525 PubMedPubMedCentralCrossRef

100.

Rajput S, Volk-Draper LD, Ran S (2013) TLR4 is a novel determinant of the response to paclitaxel in breast cancer. Mol Cancer Ther 12(8):1676–1687. https://doi.org/10.1158/1535-7163.MCT-12-1019 PubMedPubMedCentralCrossRef

101.

Volk-Draper LD, Hall KL, Wilber AC, Ran S (2017) Lymphatic endothelial progenitors originate from plastic myeloid cells activated by toll-like receptor-4. PLoS ONE 12(6):e0179257. https://doi.org/10.1371/journal.pone.0179257 PubMedPubMedCentralCrossRef

102.

Ratajczak MZ, Jadczyk T, Schneider G, Kakar SS, Kucia M (2013) Induction of a tumor-metastasis-receptive microenvironment as an unwanted and underestimated side effect of treatment by chemotherapy or radiotherapy. J ovarian Res 6(1):95. https://doi.org/10.1186/1757-2215-6-95 PubMedPubMedCentralCrossRef

103.

Chang J, Erler J (2014) Hypoxia-mediated metastasis. Adv Exp Med Biol 772:55–81. https://doi.org/10.1007/978-1-4614-5915-6_3 PubMedCrossRef

104.

Chang YS, Jalgaonkar SP, Middleton JD, Hai T (2017) Stress-inducible gene Atf3 in the noncancer host cells contributes to chemotherapy-exacerbated breast cancer metastasis. Proc Natl Acad Sci USA 114(34):E7159–E7168. https://doi.org/10.1073/pnas.1700455114 PubMedCrossRef

105.

Hai T, Hartman MG (2001) The molecular biology and nomenclature of the activating transcription factor/cAMP responsive element binding family of transcription factors: activating transcription factor proteins and homeostasis. Gene 273(1):1–11PubMedCrossRef

106.

Shaked Y, Voest EE (2009) Bone marrow derived cells in tumor angiogenesis and growth: are they the good, the bad or the evil? Biochim Biophys Acta 1796(1):1–4. https://doi.org/10.1016/j.bbcan.2009.07.002 PubMedCrossRef

107.

De Palma M, Venneri MA, Galli R, Sergi Sergi L, Politi LS, Sampaolesi M, Naldini L (2005) Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8(3):211–226. https://doi.org/10.1016/j.ccr.2005.08.002 PubMedCrossRef

108.

Shojaei F, Wu X, Malik AK, Zhong C, Baldwin ME, Schanz S, Fuh G, Gerber HP, Ferrara N (2007) Tumor refractoriness to anti-VEGF treatment is mediated by CD11b + Gr1 + myeloid cells. Nat Biotechnol 25(8):911–920. https://doi.org/10.1038/nbt1323 PubMedCrossRef

109.

Gingis-Velitski S, Loven D, Benayoun L, Munster M, Bril R, Voloshin T, Alishekevitz D, Bertolini F, Shaked Y (2011) Host response to short-term, single-agent chemotherapy induces matrix metalloproteinase-9 expression and accelerates metastasis in mice. Cancer Res 71(22):6986–6996. https://doi.org/10.1158/0008-5472.CAN-11-0629 PubMedCrossRef

110.

Shaked Y, Henke E, Roodhart JM, Mancuso P, Langenberg MH, Colleoni M, Daenen LG, Man S, Xu P, Emmenegger U, Tang T, Zhu Z, Witte L, Strieter RM, Bertolini F, Voest EE, Benezra R, Kerbel RS (2008) Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 4(3):263–273. https://doi.org/10.1016/j.ccr.2008.08.001 CrossRef

111.

Roodhart JM, Daenen LG, Stigter EC, Prins HJ, Gerrits J, Houthuijzen JM, Gerritsen MG, Schipper HS, Backer MJ, van Amersfoort M, Vermaat JS, Moerer P, Ishihara K, Kalkhoven E, Beijnen JH, Derksen PW, Medema RH, Martens AC, Brenkman AB, Voest EE (2011) Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids. Cancer Cell 20(3):370–383. https://doi.org/10.1016/j.ccr.2011.08.010 PubMedCrossRef

112.

Houthuijzen JM, Daenen LG, Roodhart JM, Voest EE (2012) The role of mesenchymal stem cells in anti-cancer drug resistance and tumour progression. Br J Cancer 106(12):1901–1906. https://doi.org/10.1038/bjc.2012.201 PubMedPubMedCentralCrossRef

113.

Stagg J (2008) Mesenchymal stem cells in cancer. Stem Cell Rev 4(2):119–124. https://doi.org/10.1007/s12015-008-9030-4 PubMedCrossRef

114.

Ridge SM, Sullivan FJ, Glynn SA (2017) Mesenchymal stem cells: key players in cancer progression. Mol Cancer 16(1):31. https://doi.org/10.1186/s12943-017-0597-8 PubMedPubMedCentralCrossRef

115.

Zhang W (2008) Mesenchymal stem cells in cancer: friends or foes. Cancer Biol Therapy 7(2):252–254CrossRef

116.

Wong RS (2011) Mesenchymal stem cells: angels or demons? J Biomed Biotechnol 2011:459510. https://doi.org/10.1155/2011/459510 PubMedPubMedCentralCrossRef

117.

Skolekova S, Matuskova M, Bohac M, Toro L, Durinikova E, Tyciakova S, Demkova L, Gursky J, Kucerova L (2016) Cisplatin-induced mesenchymal stromal cells-mediated mechanism contributing to decreased antitumor effect in breast cancer cells. Cell Commun Signal 14:4. https://doi.org/10.1186/s12964-016-0127-0 PubMedPubMedCentralCrossRef

118.

Nicolay NH, Lopez Perez R, Ruhle A, Trinh T, Sisombath S, Weber KJ, Ho AD, Debus J, Saffrich R, Huber PE (2016) Mesenchymal stem cells maintain their defining stem cell characteristics after treatment with cisplatin. Sci Rep 6:20035. https://doi.org/10.1038/srep20035 PubMedPubMedCentralCrossRef

119.

Hirose A, Tajima H, Ohta T, Tsukada T, Okamoto K, Nakanuma S, Sakai S, Kinoshita J, Makino I, Furukawa H, Hayashi H, Nakamura K, Oyama K, Inokuchi M, Nakagawara H, Miyashita T, Takamura H, Ninomiya I, Kitagawa H, Fushida S, Fujimura T, Harada S (2013) Low-dose paclitaxel inhibits the induction of epidermal-mesenchymal transition in the human cholangiocarcinoma CCKS-1 cell line. Oncol Lett 6(4):915–920. https://doi.org/10.3892/ol.2013.1494 PubMedPubMedCentralCrossRef

120.

Park SY, Kim MJ, Park SA, Kim JS, Min KN, Kim DK, Lim W, Nam JS, Sheen YY (2015) Combinatorial TGF-beta attenuation with paclitaxel inhibits the epithelial-to-mesenchymal transition and breast cancer stem-like cells. Oncotarget 6(35):37526–37543. https://doi.org/10.18632/oncotarget.6063 PubMedPubMedCentralCrossRef

121.

Yang JM, Yang GY, Medina DJ, Vassil AD, Liao J, Hait WN (1999) Treatment of multidrug resistant (MDR1) murine leukemia with P-glycoprotein substrates accelerates the course of the disease. Biochem Biophys Res Commun 266(1):167–173. https://doi.org/10.1006/bbrc.1999.1757 PubMedCrossRef

122.

Ren Y, Zhou X, Yang JJ, Liu X, Zhao XH, Wang QX, Han L, Song X, Zhu ZY, Tian WP, Zhang L, Mei M, Kang CS (2015) AC1MMYR2 impairs high dose paclitaxel-induced tumor metastasis by targeting miR-21/CDK5 axis. Cancer Lett 362(2):174–182. https://doi.org/10.1016/j.canlet.2015.03.038 PubMedCrossRef

123.

Quintavalle M, Elia L, Price JH, Heynen-Genel S, Courtneidge SA (2011) A cell-based high-content screening assay reveals activators and inhibitors of cancer cell invasion. Sci Signal 4(183):ra49. https://doi.org/10.1126/scisignal.2002032 PubMedPubMedCentralCrossRef

124.

Li QQ, Chen ZQ, Cao XX, Xu JD, Xu JW, Chen YY, Wang WJ, Chen Q, Tang F, Liu XP, Xu ZD (2011) Involvement of NF-kappaB/miR-448 regulatory feedback loop in chemotherapy-induced epithelial-mesenchymal transition of breast cancer cells. Cell Death Differ 18(1):16–25. https://doi.org/10.1038/cdd.2010.103 PubMedCrossRef

125.

Fang S, Yu L, Mei H, Yang J, Gao T, Cheng A, Guo W, Xia K, Liu G (2016) Cisplatin promotes mesenchymal-like characteristics in osteosarcoma through Snail. Oncol Lett 12(6):5007–5014. https://doi.org/10.3892/ol.2016.5342 PubMedPubMedCentralCrossRef

126.

Tajima H, Makino I, Ohbatake Y, Nakanuma S, Hayashi H, Nakagawara H, Miyashita T, Takamura H, Ohta T (2017) Neoadjuvant chemotherapy for pancreatic cancer: effects on cancer tissue and novel perspectives. Oncol Lett 13(6):3975–3981. https://doi.org/10.3892/ol.2017.6008 PubMedPubMedCentralCrossRef

127.

Roodhart JM, Langenberg MH, Daenen LG, Voest EE (2009) Translating preclinical findings of (endothelial) progenitor cell mobilization into the clinic; from bedside to bench and back. Biochim Biophys Acta 1796(1):41–49. https://doi.org/10.1016/j.bbcan.2009.04.006 PubMedCrossRef

128.

Roodhart JM, He H, Daenen LG, Monvoisin A, Barber CL, van Amersfoort M, Hofmann JJ, Radtke F, Lane TF, Voest EE, Iruela-Arispe ML (2013) Notch1 regulates angio-supportive bone marrow-derived cells in mice: relevance to chemoresistance. Blood 122(1):143–153. https://doi.org/10.1182/blood-2012-11-459347 PubMedPubMedCentralCrossRef

129.

Bourhis J, Wilson G, Wibault P, Janot F, Bosq J, Armand JP, Luboinski B, Malaise EP, Eschwege F (1994) Rapid tumor cell proliferation after induction chemotherapy in oropharyngeal cancer. Laryngoscope 104(4):468–472. https://doi.org/10.1288/00005537-199404000-00012 PubMedCrossRef

130.

El Sharouni SY, Kal HB, Battermann JJ (2003) Accelerated regrowth of non-small-cell lung tumours after induction chemotherapy. Br J Cancer 89(12):2184–2189. https://doi.org/10.1038/sj.bjc.6601418 PubMedPubMedCentralCrossRef

131.

Roodhart JM, Langenberg MH, Vermaat JS, Lolkema MP, Baars A, Giles RH, Witteveen EO, Voest EE (2010) Late release of circulating endothelial cells and endothelial progenitor cells after chemotherapy predicts response and survival in cancer patients. Neoplasia 12(1):87–94PubMedPubMedCentralCrossRef

132.

Hughes R, Qian BZ, Rowan C, Muthana M, Keklikoglou I, Olson OC, Tazzyman S, Danson S, Addison C, Clemons M, Gonzalez-Angulo AM, Joyce JA, De Palma M, Pollard JW, Lewis CE (2015) Perivascular M2 macrophages stimulate tumor relapse after chemotherapy. Cancer Res 75(17):3479–3491. https://doi.org/10.1158/0008-5472.CAN-14-3587 PubMedPubMedCentralCrossRef

133.

von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K, Loibl S (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30(15):1796–1804. https://doi.org/10.1200/JCO.2011.38.8595 CrossRef

134.

Zhang L, Riethdorf S, Wu G, Wang T, Yang K, Peng G, Liu J, Pantel K (2012) Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res 18(20):5701–5710. https://doi.org/10.1158/1078-0432.CCR-12-1587 PubMedCrossRef

135.

Pierga JY, Bidard FC, Mathiot C, Brain E, Delaloge S, Giachetti S, de Cremoux P, Salmon R, Vincent-Salomon A, Marty M (2008) Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res 14(21):7004–7010. https://doi.org/10.1158/1078-0432.CCR-08-0030 PubMedCrossRef

136.

Onstenk W, Kraan J, Mostert B, Timmermans MM, Charehbili A, Smit VT, Kroep JR, Nortier JW, van de Ven S, Heijns JB, Kessels LW, van Laarhoven HW, Bos MM, van de Velde CJ, Gratama JW, Sieuwerts AM, Martens JW, Foekens JA, Sleijfer S (2015) Improved circulating tumor cell detection by a combined EpCAM and MCAM CellSearch enrichment approach in patients with breast cancer undergoing neoadjuvant chemotherapy. Mol Cancer Ther 14(3):821–827. https://doi.org/10.1158/1535-7163.MCT-14-0653 PubMedCrossRef

137.

D’Alessio S, Blasi F (2009) The urokinase receptor as an entertainer of signal transduction. Front Biosci 14:4575–4587CrossRef

138.

LeBeau AM, Duriseti S, Murphy ST, Pepin F, Hann B, Gray JW, VanBrocklin HF, Craik CS (2013) Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancer. Cancer Res 73(7):2070–2081. https://doi.org/10.1158/0008-5472.CAN-12-3526 PubMedPubMedCentralCrossRef

139.

Hu L, Lee M, Campbell W, Perez-Soler R, Karpatkin S (2004) Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis. Blood 104(9):2746–2751. https://doi.org/10.1182/blood-2004-03-1047 PubMedCrossRef

140.

Ebrahimi S, Rahmani F, Behnam-Rassouli R, Hoseinkhani F, Parizadeh MR, Keramati MR, Khazaie M, Avan A, Hassanian SM (2017) Proinflammatory signaling functions of thrombin in cancer. J Cell Physiol 232(9):2323–2329. https://doi.org/10.1002/jcp.25753 PubMedCrossRef

141.

Wysoczynski M, Ratajczak MZ (2009) Lung cancer secreted microvesicles: underappreciated modulators of microenvironment in expanding tumors. Int J Cancer 125(7):1595–1603. https://doi.org/10.1002/ijc.24479 PubMedPubMedCentralCrossRef

142.

Gunjal PM, Schneider G, Ismail AA, Kakar SS, Kucia M, Ratajczak MZ (2015) Evidence for induction of a tumor metastasis-receptive microenvironment for ovarian cancer cells in bone marrow and other organs as an unwanted and underestimated side effect of chemotherapy/radiotherapy. J Ovarian Res 8:20. https://doi.org/10.1186/s13048-015-0141-7 PubMedPubMedCentralCrossRef

143.

Schneider G, Sellers ZP, Ratajczak MZ (2016) Induction of a tumor-metastasis-receptive microenvironment as an unwanted side effect after radio/chemotherapy and in vitro and in vivo assays to study this phenomenon. Methods Mol Biol 1516:347–360. https://doi.org/10.1007/7651_2016_323 PubMedCrossRef

144.

Janowska-Wieczorek A, Wysoczynski M, Kijowski J, Marquez-Curtis L, Machalinski B, Ratajczak J, Ratajczak MZ (2005) Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer 113(5):752–760. https://doi.org/10.1002/ijc.20657 PubMedCrossRef

145.

Janowska-Wieczorek A, Marquez-Curtis LA, Wysoczynski M, Ratajczak MZ (2006) Enhancing effect of platelet-derived microvesicles on the invasive potential of breast cancer cells. Transfusion 46(7):1199–1209. https://doi.org/10.1111/j.1537-2995.2006.00871.x PubMedCrossRef

146.

McCarty OJ, Mousa SA, Bray PF, Konstantopoulos K (2000) Immobilized platelets support human colon carcinoma cell tethering, rolling, and firm adhesion under dynamic flow conditions. Blood 96(5):1789–1797PubMed

147.

Nierodzik ML, Plotkin A, Kajumo F, Karpatkin S (1991) Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo. J Clin Investig 87(1):229–236. https://doi.org/10.1172/JCI114976 PubMedCrossRef

148.

Nieswandt B, Hafner M, Echtenacher B, Mannel DN (1999) Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 59(6):1295–1300PubMed

149.

Lopez-Soto A, Gonzalez S, Smyth MJ, Galluzzi L (2017) Control of metastasis by NK Cells. Cancer Cell 32(2):135–154. https://doi.org/10.1016/j.ccell.2017.06.009 PubMedCrossRef

150.

Balkwill F (2004) Cancer and the chemokine network. Nat Rev Cancer 4(7):540–550. https://doi.org/10.1038/nrc1388 PubMedCrossRef

151.

Bandari SK, Purushothaman A, Ramani VC, Brinkley GJ, Chandrashekar DS, Varambally S, Mobley JA, Zhang Y, Brown EE, Vlodavsky I, Sanderson RD (2017) Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior. Matrix Biol. https://doi.org/10.1016/j.matbio.2017.09.001 CrossRefPubMed

152.

Shibue T, Weinberg RA (2011) Metastatic colonization: settlement, adaptation and propagation of tumor cells in a foreign tissue environment. Semin Cancer Biol 21(2):99–106. https://doi.org/10.1016/j.semcancer.2010.12.003 PubMedCrossRef

153.

Hiratsuka S, Nakamura K, Iwai S, Murakami M, Itoh T, Kijima H, Shipley JM, Senior RM, Shibuya M (2002) MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2(4):289–300PubMedCrossRef

154.

Rossi L, Stevens D, Pierga JY, Lerebours F, Reyal F, Robain M, Asselain B, Rouzier R (2015) Impact of adjuvant chemotherapy on breast cancer survival: a real-world population. PLoS ONE 10(7):e0132853. https://doi.org/10.1371/journal.pone.0132853 PubMedPubMedCentralCrossRef

155.

Ray M, Lee YW, Scaletti F, Yu R, Rotello VM (2017) Intracellular delivery of proteins by nanocarriers. Nanomedicine 12(8):941–952. https://doi.org/10.2217/nnm-2016-0393 PubMedPubMedCentralCrossRef

156.

Reeves PM, Abbaslou MA, Kools FRW, Poznansky MC (2017) CXCR4 blockade with AMD3100 enhances Taxol chemotherapy to limit ovarian cancer cell growth. Anti-cancer Drugs 28(9):935–942. https://doi.org/10.1097/CAD.0000000000000518 PubMedCrossRef

157.

Taromi S, Kayser G, Catusse J, von Elverfeldt D, Reichardt W, Braun F, Weber WA, Zeiser R, Burger M (2016) CXCR4 antagonists suppress small cell lung cancer progression. Oncotarget 7(51):85185–85195. https://doi.org/10.18632/oncotarget.13238 PubMedPubMedCentralCrossRef

158.

Zhang J, Lu Y, Pienta KJ (2010) Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. J Natl Cancer Inst 102(8):522–528. https://doi.org/10.1093/jnci/djq044 PubMedPubMedCentralCrossRef

159.

Yao W, Ba Q, Li X, Li H, Zhang S, Yuan Y, Wang F, Duan X, Li J, Zhang W, Wang H (2017) A natural CCR2 antagonist relieves tumor-associated macrophage-mediated immunosuppression to produce a therapeutic effect for liver cancer. EBioMedicine 22:58–67. https://doi.org/10.1016/j.ebiom.2017.07.014 PubMedPubMedCentralCrossRef

160.

Hamilton JA, Cook AD, Tak PP (2016) Anti-colony-stimulating factor therapies for inflammatory and autoimmune diseases. Nat Rev Drug Discov 16(1):53–70. https://doi.org/10.1038/nrd.2016.231 PubMedCrossRef

161.

Entenberg D, Voiculescu S, Guo P, Borriello L, Wang Y, Karagiannis GS, Jones J, Baccay F, Oktay M, Condeelis J (2017) A permanent window for the murine lung enables high-resolution imaging of cancer metastasis. Nat Methods. https://doi.org/10.1038/nmeth.4511 PubMedPubMedCentralCrossRef

162.

Lewis CE, Ferrara N (2011) Multiple effects of angiopoietin-2 blockade on tumors. Cancer Cell 19(4):431–433. https://doi.org/10.1016/j.ccr.2011.03.016 PubMedCrossRef

163.

Mazzieri R, Pucci F, Moi D, Zonari E, Ranghetti A, Berti A, Politi LS, Gentner B, Brown JL, Naldini L, De Palma M (2011) Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 19(4):512–526. https://doi.org/10.1016/j.ccr.2011.02.005 PubMedCrossRef

164.

Mammoto T, Jiang E, Jiang A, Mammoto A (2013) Extracellular matrix structure and tissue stiffness control postnatal lung development through the lipoprotein receptor-related protein 5/Tie2 signaling system. Am J Respir Cell Mol Biol 49(6):1009–1018. https://doi.org/10.1165/rcmb.2013-0147OC PubMedCrossRef

165.

Dalton AC, Shlamkovitch T, Papo N, Barton WA (2016) Constitutive association of Tie1 and Tie2 with endothelial integrins is functionally modulated by angiopoietin-1 and fibronectin. PLoS ONE 11(10):e0163732. https://doi.org/10.1371/journal.pone.0163732 PubMedPubMedCentralCrossRef

166.

Cascone I, Napione L, Maniero F, Serini G, Bussolino F (2005) Stable interaction between alpha5beta1 integrin and Tie2 tyrosine kinase receptor regulates endothelial cell response to Ang-1. J Cell Biol 170(6):993–1004. https://doi.org/10.1083/jcb.200507082 PubMedPubMedCentralCrossRef

167.

Spiegel A, Brooks MW, Houshyar S, Reinhardt F, Ardolino M, Fessler E, Chen MB, Krall JA, DeCock J, Zervantonakis IK, Iannello A, Iwamoto Y, Cortez-Retamozo V, Kamm RD, Pittet MJ, Raulet DH, Weinberg RA (2016) Neutrophils suppress intraluminal NK Cell-mediated tumor cell clearance and enhance extravasation of disseminated carcinoma cells. Cancer Discov 6(6):630–649. https://doi.org/10.1158/2159-8290.CD-15-1157 PubMedPubMedCentralCrossRef

Titel: Chemotherapy-induced metastasis: mechanisms and translational opportunities
verfasst von: George S. Karagiannis
John S. Condeelis
Maja H. Oktay
Publikationsdatum: 06.01.2018
Verlag: Springer Netherlands
Erschienen in: Clinical & Experimental Metastasis / Ausgabe 4/2018
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-017-9870-x

Neu im Fachgebiet Onkologie

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Chemotherapy-induced metastasis: mechanisms and translational opportunities

Abstract

Neu im Fachgebiet Onkologie

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Update Onkologie

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2018

Potential impact of invasive surgical procedures on primary tumor growth and metastasis

Editorial: Therapy-induced metastasis

Implicating anaesthesia and the perioperative period in cancer recurrence and metastasis

The Kraken Wakes: induced EMT as a driver of tumour aggression and poor outcome

Surgical stress response and promotion of metastasis in colorectal cancer: a complex and heterogeneous process

The challenge of drug resistance in cancer treatment: a current overview

Neu im Fachgebiet Onkologie

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Update Onkologie